论文部分内容阅读
由上海医药工业研究院研制的抗癌新药司莫司汀已由浙江省卫生厅批准浙南制药厂生产。司莫司汀(MeCCNU)又名甲环亚硝脲。是继卡氮芥(BCNU)、环基亚硝脲(CCNU)之后的第三只亚硝脲类抗肿瘤药物。动物实验表明,司莫司汀对多种动物实验肿瘤的抗肿瘤活性和卡氮芥、环基亚硝脲相似。皮下接种的Lewis肺癌是一种对化疗药物最不敏感的瘤株,但司莫司汀的作用明显优于卡氮芥和环基亚硝脲。司莫司汀对相对不敏感的实验肿瘤第一代C_3H乳癌的作用,比卡
The new anticancer drug, Motustine, developed by the Shanghai Institute of Pharmaceutical Industry, has been approved by the Zhejiang Provincial Department of Health for the production of southern Zhejiang pharmaceutical factory. Semustine (MeCCNU) also known as nail ring nitrosourea. Is the second nitrosourea antineoplastic drug following BCNU and cyclothiocarbamide (CCNU). Animal experiments show that the anti-tumor activity of semustine on a variety of animal experiments and carmustine, carbocyanyl urea similar. Lewis lung carcinoma subcutaneously is a tumor that is the least susceptible to chemotherapeutic drugs, but the effect of semustine is significantly superior to that of both Carbox (mechlorethamine) and Cyclocarbamide. Effect of semustine on relatively insensitive first-generation C_3H breast cancer in experimental tumors,